Reported results
- Net earnings were $1.2 billion, or $1.71 per diluted common share, up 34.5% year-over-year.
- Non-GAAP adjusted diluted net earnings per common share grew 11.5% to $2.11.
- Revenues increased 8.5% year-over-year to $6.6 billion.
- Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year and non-GAAP core revenue increased 3.0% year-over-year.
- Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion.
Guidance
- For the fourth quarter 2026, non-GAAP core revenue excluding respiratory revenue is anticipated to increase in the 4.0% to 5.0% range year-over-year.
- For the fourth quarter 2026, respiratory revenue is expected to be an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%.
- For full year 2026, non-GAAP adjusted diluted net earnings per common share guidance was increased to a range of $8.57 to $8.62.
- For the fourth quarter 2026, non-GAAP adjusted operating profit margin is expected to be approximately 29.5%.
Notes
Beginning with the third quarter 2026 Form 10-Q, Danaher is excluding from core sales growth and core sales excluding respiratory testing the impact of tariff refunds returned or to be returned to customers.
Price and volatility reaction
The stock moved +4.3% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -10.4 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 224.24 | 2026-10-20 |
| Close after release | 233.86 | 2026-10-21 |
| Realised move | +4.3% | close to close |
| 30d ATM IV change | -10.4 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-20 (8-K, Item 2.02). Read the original filing on sec.gov.
